Skip to content

News

The Overview: July 2023

The Overview: July 2023

OCRA-Funded Study Targets Immunotherapy OCRA grantees and their Roswell Park Comprehensive Cancer Center colleagues published results from an exciting study detailing a new approach to adoptive T-cell therapy that may help improve immunotherapy options for ovarian cancer patients. Learn more about the findings from the research team, which included Dr. Bob McGray, OCRA grantee, and Dr. Kunle Odunsi, … Continued

Study: Gynecologic Cancer Survivors Fear Recurrence Regardless of Prognosis

Study: Gynecologic Cancer Survivors Fear Recurrence Regardless of Prognosis

A recent study from Cancer Nursing has shed more light on the profound impact gynecologic cancer has on survivors, even after treatment. In particular, the study highlighted the prevalence of fear of recurrence among gynecologic cancer survivors, regardless of their prognosis, and underscores the importance of support programs to address survivors’ needs adequately. Through in-depth … Continued

Chi Lam Au Yeung, PhD | Meet a Scientist

Chi Lam Au Yeung, PhD | Meet a Scientist

Dr. Chi Lam Au Yeung of the University of Texas MD Anderson Cancer Center is a 2022 recipient of OCRA’s Early Career Investigator Grant. Her OCRA-funded project is focused on studying molecules produced by ovarian cancer cells in order to gain new insights into the interrelationship between different cell types in the progression of this … Continued

Facing Down Four Recurrences and Finding Strength in Community

Facing Down Four Recurrences and Finding Strength in Community

Janice Paulshock first began connecting with others in the ovarian cancer community in 1999 after being diagnosed with Stage 3C high-grade serous carcinoma. Twenty-plus years and four recurrences later, she remains committed to offering support to gynecologic cancer patients through her role as a mentor in OCRA’s Woman to Woman program. Find out how her … Continued

Jill McGill Raises Awareness at U.S. Women’s Open at Pebble Beach

Jill McGill Raises Awareness at U.S. Women’s Open at Pebble Beach

Jill McGill, reigning champion of the U.S. Senior Women’s Open, continued to champion the ovarian cancer cause at last week’s U.S. Women’s Open at Pebble Beach, handing out special ball-markers featuring her signature on one side, and a QR code leading to OCRA’s website on the other. McGill’s campaign to make a difference is in … Continued

Overcoming Racial Disparities in Genetic Testing

Overcoming Racial Disparities in Genetic Testing

In a new article published in Everyday Health, experts spoke about the disparities Black Americans face when diagnosed with ovarian cancer, exploring reasons why these disparities may exist, and offering recommendations for Black individuals who are diagnosed with ovarian, fallopian tube, or primary peritoneal cancer. In particular, Black Americans should be aware of the importance … Continued

The Overview: June 2023

The Overview: June 2023

Update to Clinical Guidelines: Special Circumstance Chemotherapy Approvals Last month, we reported news of an ongoing shortage of chemotherapy drugs essential to ovarian cancer treatment. Though the shortage continues, patients affected now have more options. In early June, the National Comprehensive Care Network’s (NCCN) Clinical Practice Guidelines were updated to approve oxaliplatin-based regimens like docetaxel / oxaliplatin … Continued

Special Summer Programming Offers Support and Opportunities to Connect

Special Summer Programming Offers Support and Opportunities to Connect

Summer is officially here! Strengthen your connection to community this season with special support offerings, interactive roundtables and summer-themed sessions for those impacted by ovarian and other gynecologic cancers. And no need to leave the comfort of your climate-controlled home to attend — all meetings will be held online. “This summer, we’re offering more choices … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.